Qiagen N.V. (NYSE:QGEN) Given Average Rating of “Hold” by Analysts

Shares of Qiagen N.V. (NYSE:QGEN) have earned an average recommendation of “Hold” from the twelve brokerages that are covering the company, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, six have issued a hold recommendation, four have assigned a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1 year price target among brokers that have issued ratings on the stock in the last year is $44.9789.

A number of research analysts recently weighed in on the stock. Robert W. Baird set a $43.00 target price on shares of Qiagen and gave the company an “outperform” rating in a report on Wednesday, April 29th. TD Cowen reissued a “hold” rating and issued a $40.00 target price (down from $46.00) on shares of Qiagen in a report on Thursday, May 7th. Weiss Ratings lowered shares of Qiagen from a “hold (c-)” rating to a “sell (d+)” rating in a report on Friday, May 29th. Zacks Research raised shares of Qiagen from a “strong sell” rating to a “hold” rating in a report on Wednesday, April 29th. Finally, JPMorgan Chase & Co. cut their target price on shares of Qiagen from $60.00 to $45.00 and set an “overweight” rating for the company in a report on Wednesday, April 29th.

Qiagen Trading Down 1.5%

Qiagen stock opened at $36.66 on Thursday. The stock has a market cap of $7.55 billion, a P/E ratio of 19.14, a PEG ratio of 3.70 and a beta of 0.66. The company has a debt-to-equity ratio of 0.49, a current ratio of 3.21 and a quick ratio of 2.57. Qiagen has a 1 year low of $32.53 and a 1 year high of $57.81. The firm’s 50 day moving average price is $36.83 and its 200-day moving average price is $43.70.

Qiagen (NYSE:QGEN) last posted its earnings results on Thursday, May 7th. The company reported $0.54 earnings per share for the quarter, meeting analysts’ consensus estimates of $0.54. Qiagen had a net margin of 19.16% and a return on equity of 14.40%. The firm had revenue of $492.32 million during the quarter, compared to analyst estimates of $496.15 million. During the same period last year, the firm posted $0.56 earnings per share. On average, equities analysts predict that Qiagen will post 2.43 earnings per share for the current fiscal year.

Qiagen Increases Dividend

The firm also recently announced an annual dividend, which will be paid on Tuesday, July 14th. Investors of record on Tuesday, July 7th will be issued a $0.35 dividend. This represents a dividend yield of 104.0%. This is a boost from Qiagen’s previous annual dividend of $0.26. The ex-dividend date of this dividend is Tuesday, July 7th. Qiagen’s payout ratio is 13.61%.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the company. Danske Bank A S bought a new position in Qiagen during the third quarter valued at $36,000. Smartleaf Asset Management LLC boosted its stake in shares of Qiagen by 1,383.3% during the third quarter. Smartleaf Asset Management LLC now owns 890 shares of the company’s stock valued at $39,000 after purchasing an additional 830 shares during the period. Manchester Capital Management LLC purchased a new stake in shares of Qiagen during the fourth quarter valued at $42,000. Global Retirement Partners LLC boosted its stake in shares of Qiagen by 279.9% during the fourth quarter. Global Retirement Partners LLC now owns 1,155 shares of the company’s stock valued at $52,000 after purchasing an additional 851 shares during the period. Finally, Allworth Financial LP boosted its stake in shares of Qiagen by 23.2% during the third quarter. Allworth Financial LP now owns 1,358 shares of the company’s stock valued at $61,000 after purchasing an additional 256 shares during the period. Institutional investors own 70.00% of the company’s stock.

Qiagen Company Profile

Qiagen NV (NYSE: QGEN) is a global provider of sample and assay technologies designed to enable molecular testing in the fields of molecular diagnostics, applied testing, academic research and pharmaceutical development. The company’s solutions span the full workflow of nucleic acid and protein analysis, offering customers standardized kits, instruments and software tools that streamline the preparation, detection and quantification of DNA, RNA and proteins.

The company’s product portfolio includes nucleic acid extraction and purification systems, polymerase chain reaction (PCR) reagents and instrumentation, digital PCR platforms, next-generation sequencing (NGS) library‐preparation kits and proteomics solutions.